Ratings Pacific Biosciences of California, Inc. Deutsche Boerse AG

Equities

P09

US69404D1081

Real-time Estimate Tradegate Other stock markets 12:35:37 18/05/2024 am IST			5-day change	1st Jan Change
1.862 ^EUR	-11.59%		+18.82%	-77.97%

15/05	Pacific Biosciences, Ambry Genetics Selected to Sequence up to 7,000 Human Genomes	MT
15/05	Morgan Stanley Adjusts Price Target on Pacific Biosciences of California to $4 From $10, Maintains Equal-Weight Rating	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 61% by 2026.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
The company's "enterprise value to sales" ratio is among the highest in the world.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
Over the past four months, analysts' average price target has been revised downwards significantly.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.	-77.97%	60Cr	-
THERMO FISHER SCIENTIFIC	+11.83%	23TCr	B
DANAHER CORPORATION	+14.54%	20TCr	B-
INTUITIVE SURGICAL, INC.	+17.78%	14TCr	B-
BOSTON SCIENTIFIC CORPORATION	+28.27%	11TCr	A-
SIEMENS HEALTHINEERS AG	+0.53%	6.59TCr	A-
EDWARDS LIFESCIENCES CORPORATION	+16.51%	5.43TCr	B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+6.33%	5.24TCr	B+
AGILENT TECHNOLOGIES, INC.	+11.20%	4.52TCr	A
GE HEALTHCARE TECHNOLOGIES INC.	+5.20%	3.71TCr	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes